Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Rik C. Schoemaker"'
Autor:
Matthew Fidler, Richard Hooijmaijers, Mirjam N. Trame, Justin J. Wilkins, Rik C. Schoemaker, Yuan Xiong, Christian Laveille, Wenping Wang, Teun M. Post
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 923-930 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
The free and open-source package nlmixr implements pharmacometric nonlinear mixed effects model parameter estimation in R. It provides a uniform language to define pharmacometric models using ordinary differential equations. Performances of the stoch
Autor:
Lene Alifrangis, Rikke Hald, Michael Kragh, Niels Jorgen Ostergaard Skartved, Rik C. Schoemaker, Scott Kopetz, Janet R. Wade, Josep Tabernero, C. Montagut
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 47:5-18
Sym004 is an equimolar mixture of two monoclonal antibodies, futuximab and modotuximab, which non-competitively block the epidermal growth factor receptor (EGFR). Sym004 has been clinically tested for treatment of solid tumors. The present work chara
Autor:
Justin J. Wilkins, Matthew Fidler, Rik C. Schoemaker, Richard Hooijmaijers, Yuan Xiong, Wenping Wang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 4, Pp 283-285 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Autor:
Richard Hooijmaijers, Justin J. Wilkins, Wenping Wang, Yuan Xiong, Teun M. Post, Rik C. Schoemaker, Matthew Fidler, Mirjam N. Trame
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 621-633 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
nlmixr is a free and open-source R package for fitting nonlinear pharmacokinetic (PK), pharmacodynamic (PD), joint PK-PD, and quantitative systems pharmacology mixed-effects models. Currently, nlmixr is capable of fitting both traditional compartment
Publikováno v:
Epilepsy Research. 149:13-16
A combined adult and pediatric population pharmacokinetic model including covariate effects was developed; simulations were subsequently performed to guide intravenous pediatric dosing adaptations. Two pharmacokinetic trials with sparse blood samplin
Publikováno v:
The Journal of Clinical Pharmacology. 59:541-547
A pediatric population pharmacokinetic model including covariate effects was developed using data from 2 clinical trials in pediatric patients with epilepsy (SP0847 and SP1047). Lacosamide plasma concentration-time data (n = 402) were available from
Autor:
Rui Zhu, Kit Wong, Melissa Cheu, Gaohong She, Aurelie Gautier, Angelica Quartino, Theodore A. Omachi, Xianbin Tian, Rik C. Schoemaker, Wendy S. Putnam, Ryan Owen, Shweta Vadhavkar, Justin J. Wilkins
Publikováno v:
Pulmonary pharmacologytherapeutics. 71
The anti-immunoglobulin E (IgE) antibody, omalizumab (Xolair), is approved in the United States for the treatment of allergic asthma and chronic spontaneous urticaria, and has recently been studied for the treatment of nasal polyposis following compl
Publikováno v:
Epilepsy Research. 137:95-100
Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A, recently approved as adjunctive therapy in the treatment of focal (partial-onset) seizures in patients 16 years of age and older with epilepsy. The goal of the present
Publikováno v:
Clinical Pharmacokinetics
Introduction Prediction of brivaracetam effects in children was obtained by scaling an existing adult pharmacokinetic/pharmacodynamic (PK/PD) model for brivaracetam to children, using an existing population PK model for brivaracetam in children. The
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The aims of the study were to develop a population pharmacokinetic model of orally administered brivaracetam in paediatric patients and to provide dosing suggestions. Methods Analysis included 600 brivaracetam plasma concentrations from a pha